A similar response is expected by changing the concentration of the DNA tethers, which could also be replaced by other types of ligand-receptor pairs, such as antibodies.

Better drugs will be designed once more is understood about receptor-ligand interactions and more information about targets is available from high-resolution studies of their properties in solution.

Subsequently, we monitored the ligand-dependent HER profiles based on receptor expression, phosphorylation, and dimerization in conjunction with measurements of cellular susceptibility to gefitinib.